AI Summary
→ WHAT IT COVERS Marwan Fathallah, CEO of DIA Global with 30 years in life sciences, outlines the leadership framework required to move products from concept to commercialization, covering cross-functional team structure, daily management cadence, KPI design, conflict resolution, and the cultural balance between innovation and regulatory rigor. → KEY INSIGHTS - **Cross-Functional Integration:** Embed regulatory, marketing, clinical, and R&D stakeholders into the product development process from day one rather than treating compliance as a final gate. When these disciplines coexist early, they calibrate each other's risk tolerance, accelerating both innovation and submission readiness without sacrificing scientific rigor or safety standards. - **Project Room Cadence:** Structure cross-functional teams around a physical or virtual project room with daily stand-up meetings where each function reports KPI status — on track or off track — against a visible timeline. The project manager acts as an independent Maestro, not embedded in any single function, to maintain neutrality and accountability across all stakeholders. - **Leading Indicator KPIs:** Avoid single long-horizon KPIs like "complete verification and validation." Instead, map milestone-based leading indicators — feasibility test results, dry-run clinical study completion — that signal trajectory toward the final goal. Without these intermediate markers, risk goes unmanaged and teams face avoidable late-stage surprises that compress timelines and inflate costs. - **Conflict Resolution Protocol:** Address disruptive team dynamics immediately and privately using observation-based language — "I am seeing" rather than accusatory framing — which prevents debate about intent. If behavior persists, escalate to the function head framed as a check-in rather than a complaint, then surface team dynamics formally in the weekly leadership update with proposed options. - **Systems Thinking Over Silos:** Train team members to understand product development as an interdependent system where delaying a regulatory submission to incorporate stronger clinical data may increase approval probability despite disrupting the business plan. Leaders who have held roles across the full development cycle from concept to post-market are measurably less defensive and more effective at these trade-off decisions. → NOTABLE MOMENT Fathallah argues that when teams lack transparent communication, individuals fill the information vacuum by constructing their own internal narratives — and those self-generated stories are almost always worse than the actual situation, making transparency a risk-mitigation tool as much as a cultural value. 💼 SPONSORS None detected 🏷️ Cross-Functional Leadership, Product Development, Life Sciences, Regulatory Affairs, Project Management